Garadacimab Pharmacokinetic and Safety Profiles Show No Impact of Concomitant Medication Use in Hereditary Angioedema

Paul K Keith¹, John Anderson², H Henry Li³, Markus Magerl⁴⁻⁶, Regina Treudler⁴, Fiona Glassman^{7*}, Harsha Shetty⁸, John-Philip Lawo⁹, Maressa Pollen⁸, Timothy J Craig^{10,11}


 Trait and Allergy, Chevy Chase, MD, USA; ⁴Institute for Translational Medicine and Pharmacology, Berlin, Germany; ⁵Freie Universität zu Berlin, Berlin, Germany; ⁵Freie Universität Berlin, Germany; ⁵Freie Universität zu Berlin, Berlin, Germany; ⁶Freie Universität zu Berlin, Berlin, Berlin, Germany; ⁶Freie Universität zu Berlin, Germany; ⁸Freie Universität zu Berlin, Berlin, Germany; ⁸Freie Universität zu Berlin, Germany; ⁹Freie] * Allergy, Asthma and Immunology, Department of Prussia, PA, USA; * CSL Behring, King of Prussia, PA, USA; * CSL Behring, King of Prussia, PA, USA; * CSL Innovation of the study, Fiona Glassman moved from CSL Behring, King of Prussia, PA, USA; * CSL Behring, King of Prussia, PA, USA

CONCLUSIONS

- long-term prophylaxis of HAE attacks^{1,2,6}
- (VANGUARD) and Phase 3 open-label extension (OLE) studies^{1,2,7}
- medication or on-demand therapy for HAE, and immunogenicity⁹

- medications^{*} in the Phase 2, pivotal Phase 3, and Phase 3 OLE studies
- patients receiving garadacimab and concomitant hemostasis-impacting medications[†]
- Bayes estimates

nedications with indirect impact on hemostasis



garadacimab 75, 200, or 600 mg SC, respectively.

REFERENCES:

1. Craig TJ et al. Lancet 2023;401:1079–1090; 2. Reshef A et al. Allergy 2025;80:545–556; 3. Busse PJ et al. J Allergy Clin Immunol Pract 2021;9:132–150.e3; 4. Davis AE 3rd. Transfus Apher Sci 2003;29:195–203; 5. Maurer M et al. Allergy 2022;77:1961–1990; 6. Craig TJ et al. Lancet Hematol 2024;11:e436–e447; 7. Craig TJ et al. Lancet 2022;399:945–955; 8. Cohn D et al. Ann Allergy Asthma Immunol 2024;S31-S32; 9. Glassman F et al. J Allergy Clin Immunol 2024;153:AB4; 10. McKenzie A et al. Clin Transl Sci 2022;15: 626–637; 11. Glassman F et al. J Clin Pharmacol 2024 doi: 10.1002/jcph.6162 (online ahead of print).


No safety concerns were identified for patients receiving garadacimab and concomitant analgesic, antihistamine, anti-inflammatory, or antibacterial medications Garadacimab had no impact on hemostasis in patients receiving concomitant hemostasis-impacting medication, and its safety profile was consistent with that of patients receiving garadacimab alone • The pharmacokinetic (PK) profile of garadacimab was unaffected by the use of concomitant medications

DISCLOSURES:


This study was funded by CSL Behring LLC. Medical writing support was provided by Hazel Shepherd, DPhil, of Helix, OPEN Health Communications, and funded by CSL Behring, in accordance with Good Publication Practice guidelines (GPP 2022).

No impact of co	ommon concon
-----------------	--------------









Concomitant medications had **no impact** on the PK of garadacimab

In the box plots, median values are represented by a solid line in the center of the box. Boxes indicate the IQR, with whiskers extending to 1.5 × IQR. AUC_{touse}, area under the concentration-time curve for a dosing interval at steady state; CL, total drug clearance; HAE, hereditary angioedema; IQR, interquartile range; PK, pharmacokinetic; V2, volume of distribution.

nitant medications on the PK of garadacimab

Figure 2: Predicted PK parameters for garadacimab in the presence of or without concomitant medication with: A) analgesics, B) antihistamines, C) anti-inflammatories, and D) antibacterials

A) Analgesics ____ _____ n=48 n=134

C) Anti-inflammatories

D) Antibacterials



Scan the QR code to acces the poste

B) Antihistamines

